Stoke Therapeutics (STOK) Net Cash Flow (2018 - 2026)
Stoke Therapeutics' quarterly Net Cash Flow came in at $74.4 million in Q1 2026, down 49.3% year-on-year from $146.8 million in Q1 2025, and up 8911.99% quarter-over-quarter from $826000.0 in Q4 2025.
Stoke Therapeutics has reported Net Cash Flow for 9 years, with the latest figure at $74.4 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow fell 49.3% year-over-year to $74.4 million; the trailing twelve-month figure through Mar 2026 stood at -$116.2 million (down 220.5% YoY), and the FY2025 full-year result was -$43.8 million, up 30.67% from the prior year.
- Net Cash Flow for Q1 2026 stood at $74.4 million, up from $826000.0 in the prior quarter.
- The five-year high for Net Cash Flow was $146.8 million in Q1 2025, with the low at -$173.3 million in Q2 2025.
- Average Net Cash Flow over 5 years is $818588.2, with a median of $160000.0 recorded in 2022.
- Year-over-year, Net Cash Flow plunged 1986.41% in 2024 and jumped 1241.69% in 2025.
- Tracing STOK's Net Cash Flow over 5 years: stood at $160000.0 in 2022, then jumped by 815.62% to $1.5 million in 2023, then plunged by 1588.46% to -$21.8 million in 2024, then soared by 103.79% to $826000.0 in 2025, then surged by 8911.99% to $74.4 million in 2026.
- The last three Net Cash Flow figures came in at $74.4 million (Q1 2026), $826000.0 (Q4 2025), and -$18.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | 74.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.44 Mn |
| Mar 31, 2026 | 74.44 Mn |
| Dec 31, 2025 | 826,000.00 |
| Dec 31, 2025 | 826,000.00 |
| Sep 30, 2025 | -18.15 Mn |
| Sep 30, 2025 | -18.15 Mn |
| Jun 30, 2025 | -173.35 Mn |
| Jun 30, 2025 | -173.35 Mn |
| Mar 31, 2025 | 146.83 Mn |
| Mar 31, 2025 | 146.83 Mn |
| Dec 31, 2024 | -21.81 Mn |
| Dec 31, 2024 | -21.81 Mn |
| Sep 30, 2024 | -43.46 Mn |
| Sep 30, 2024 | -43.46 Mn |
| Jun 30, 2024 | 14.90 Mn |
| Jun 30, 2024 | 14.90 Mn |
| Mar 31, 2024 | -12.86 Mn |
| Mar 31, 2024 | -12.86 Mn |
| Dec 31, 2023 | 1.47 Mn |
| Dec 31, 2023 | 1.47 Mn |
| Sep 30, 2023 | -2.08 Mn |
| Sep 30, 2023 | -2.08 Mn |
| Jun 30, 2023 | 1.72 Mn |
| Jun 30, 2023 | 1.72 Mn |
| Mar 31, 2023 | 76.78 Mn |
| Mar 31, 2023 | 76.78 Mn |
| Dec 31, 2022 | 160,000.00 |
| Dec 31, 2022 | 160,000.00 |
| Sep 30, 2022 | 45.64 Mn |
| Sep 30, 2022 | 45.64 Mn |
| Jun 30, 2022 | -16.36 Mn |
| Jun 30, 2022 | -16.36 Mn |
| Mar 31, 2022 | -60.78 Mn |
| Mar 31, 2022 | -60.78 Mn |
| Dec 31, 2021 | -4.29 Mn |
| Dec 31, 2021 | -4.29 Mn |
| Sep 30, 2021 | -19.54 Mn |
| Sep 30, 2021 | -19.54 Mn |
| Jun 30, 2021 | -98.43 Mn |
| Jun 30, 2021 | -98.43 Mn |
| Mar 31, 2021 | -19.79 Mn |
| Mar 31, 2021 | -19.79 Mn |
| Dec 31, 2020 | 95.85 Mn |
| Dec 31, 2020 | 95.85 Mn |
| Sep 30, 2020 | -10.47 Mn |
| Sep 30, 2020 | -10.47 Mn |
| Jun 30, 2020 | -9.36 Mn |
| Jun 30, 2020 | -9.36 Mn |
| Mar 31, 2020 | -11.18 Mn |
| Mar 31, 2020 | -11.18 Mn |
| Dec 31, 2019 | -10.58 Mn |
| Dec 31, 2019 | -10.58 Mn |
| Sep 30, 2019 | -9.63 Mn |
| Sep 30, 2019 | -9.63 Mn |
| Jun 30, 2019 | 143.97 Mn |
| Jun 30, 2019 | 143.97 Mn |
| Mar 31, 2019 | -6.69 Mn |
| Mar 31, 2019 | -6.69 Mn |
| Dec 31, 2018 | 86.18 Mn |
| Dec 31, 2018 | 86.18 Mn |
| Sep 30, 2018 | 9.82 Mn |
| Sep 30, 2018 | 9.82 Mn |